Retatrutide
Description
Retatrutide (developmental code: LY3437943) is a groundbreaking investigational peptide developed by Eli Lilly that represents the next evolution in obesity and type 2 diabetes pharmacotherapy. Unlike previous weight loss medications that target one or two metabolic pathways, retatrutide is the first triple receptor agonist that simultaneously activates three key hormonal pathways: GLP-1, GIP, and glucagon receptors.
First publicly identified around 2019, retatrutide has generated significant attention in the medical community after demonstrating unprecedented weight loss results in clinical trials—with participants losing up to 24.2% of their body weight in 48 weeks, surpassing the efficacy of current market-leading medications like semaglutide (Wegovy) and tirzepatide (Mounjaro).
As obesity affects over 42% of American adults and is linked to numerous comorbidities including cardiovascular disease, type 2 diabetes, and certain cancers, the development of more effective pharmacological interventions like retatrutide addresses a critical public health need.
Certificate of Analysis
Every batch of Retatrutide is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.
Request a COAResearch Protocol
Full dose-by-dose reconstitution & dosing protocol for Retatrutide.
View Research Protocol →Research protocol for this size is coming soon.
For laboratory and scientific research use only. Not medical advice.
For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.
